1 Harding, R. Palliative care as an essential component of the HIV care continuum. The lancet. HIV, doi:10.1016/s2352-3018(18)30110-3 (2018).
2 de Villiers, S., Swanepoel, A., Bester, J. & Pretorius, E. Novel Diagnostic and Monitoring Tools in Stroke: an Individualized Patient-Centered Precision Medicine Approach. Journal of atherosclerosis and thrombosis 23, 493-504, doi:10.5551/jat.32748 (2015).
3 Page, M. J., Bester, J. & Pretorius, E. The inflammatory effects of TNF-alpha and complement component 3 on coagulation. Scientific reports 8, 1812, doi:10.1038/s41598-018-20220-8 (2018).
4 Pretorius, E. & Lipinski, B. Thromboembolic ischemic stroke changes red blood cell morphology. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 22, 241-242, doi:10.1016/j.carpath.2012.11.005 (2013).
5 Pretorius, E., Swanepoel, A. C., DeVilliers, S. & Bester, J. Blood clot parameters: Thromboelastography and scanning electron microscopy in research and clinical practice. Thrombosis research 154, 59-63, doi:10.1016/j.thromres.2017.04.005 (2017).
6 van Rooy, M. J., Duim, W., Ehlers, R., Buys, A. V. & Pretorius, E. Platelet hyperactivity and fibrin clot structure in transient ischemic attack individuals in the presence of metabolic syndrome: a microscopy and thromboelastography study. Cardiovascular diabetology 14, 86, doi:10.1186/s12933-015-0249-5 (2015).
7 Bester, J., Matshailwe, C. & Pretorius, E. Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β, IL-6 and IL-8. Cytokine, S1043-4666(1018)30007-30003. (2018).
8 Bester, J. & Pretorius, E. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Scientific Reports 6, 32188, doi:10.1038/srep32188 (2016).
9 Wada, N. I. et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS (London, England) 29, 463-471, doi:10.1097/qad.0000000000000545 (2015).
10 Siti, H. N., Kamisah, Y. & Kamsiah, J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascular pharmacology 71, 40-56, doi:10.1016/j.vph.2015.03.005 (2015).
11 Khambhati, J. et al. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities. Atherosclerosis 276, 1-9, doi:10.1016/j.atherosclerosis.2018.07.007 (2018).
12 Teer, E. & Essop, M. F. HIV and Cardiovascular Disease: Role of Immunometabolic Perturbations. Physiology (Bethesda, Md.) 33, 74-82, doi:10.1152/physiol.00028.2017 (2018).
13 Deeks, S. G., Tracy, R. & Douek, D. C. Systemic effects of inflammation on health during chronic HIV infection. Immunity 39, 633-645, doi:10.1016/j.immuni.2013.10.001 (2013).
14 Baker, J. V. et al. HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation. Journal of the American Heart Association 2, e000264, doi:10.1161/jaha.113.000264 (2013).
15 Vululi, S. T. et al. Prevalence of lower limb deep venous thrombosis among adult HIV positive patients attending an outpatient clinic at Mulago Hospital. AIDS research and therapy 15, 3, doi:10.1186/s12981-018-0191-1 (2018).
16 Malek, J., Rogers, R., Kufera, J. & Hirshon, J. M. Venous thromboembolic disease in the HIV-infected patient. The American journal of emergency medicine 29, 278-282, doi:10.1016/j.ajem.2009.09.034 (2011).
17 Louw, S., Jacobson, B. F. & Buller, H. Human immunodeficiency virus infection and acute deep vein thromboses. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 14, 352-355, doi:10.1177/1076029607304411 (2008).
18 Reiter, M., Bucek, R. A., Koca, N., Dirisamer, A. & Minar, E. Deep vein thrombosis and systemic inflammatory response: a pilot trial. Wiener klinische Wochenschrift 115, 111-114 (2003).
19 Mosevoll, K. A. et al. Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis. Frontiers in medicine 5, 147, doi:10.3389/fmed.2018.00147 (2018).
20 Aquila, A. M. Deep Venous Thrombosis. Journal of Cardiovascular Nursing 15, 25-44 (2001).
21 Malek, J., Rogers, R., Kufera, J. & Hirshon, J. M. Venous thromboembolic disease in the HIV-infected patient. The American Journal of Emergency Medicine 29, 278-282, doi:https://doi.org/10.1016/j.ajem.2009.09.034 (2011).
22 Kiser, K. L. & Badowski, M. E. Risk factors for venous thromboembolism in patients with human immunodeficiency virus infection. Pharmacotherapy 30, 1292-1302 (2010).
23 Jacobson, M. C., Dezube, B. J. & Aboulafia, D. M. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis 39, 1214-1222 (2004).
24 Jong, E., Louw, S. & Meijers, J. C. The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy. AIDS Patient Care STDS 23, 1001-1007 (2009).
25 Aboulafia, D. An update on HIV-associated venous thromboembolism in the era of highly active antiretroviral therapy. J Coagul Disord 2, 49-56 (2010).
26 Goldhaber, S. Z. & Bounameaux, H. Pulmonary embolism and deep vein thrombosis. Lancet 379, 1835-1846, doi:10.1016/s0140-6736(11)61904-1 (2012).
27 Di Nisio, M., van Es, N. & Büller, H. R. Deep vein thrombosis and pulmonary embolism. The Lancet 388, 3060-3073, doi:https://doi.org/10.1016/S0140-6736(16)30514-1 (2016).
28 Büller, H. R., ten Cate-Hoek, A. J., Hoes, A. W. & et al. SAfely ruling out deep venous thrombosis in primary care. Annals of Internal Medicine 150, 229-235, doi:10.7326/0003-4819-150-4-200902170-00003 (2009).
29 Pretorius, E. et al. Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics. Cardiovascular diabetology 14, 30, doi:10.1186/s12933-015-0192-5 (2015).
30 Tortora, G. J. & Grabowski, S. R. Principles of anatomy and physiology. 8th ed. edn, 1 volume (various pagings) : illustrations (some color) ; 29 cm + 1 atlas (v, 24 pages : color illustrations ; 28 cm) (HarperCollins College, 1996).
31 Lawrie, D. et al. Local reference ranges for full blood count and CD4 lymphocyte count testing. Samj South African Medical Journal 99, 243-248 (2009).
32 Kreuzer, K. A. & Rockstroh, J. K. Pathogenesis and pathophysiology of anemia in HIV infection. Annals of Hematology 75, 179-187, doi:10.1007/s002770050340 (1997).
33 Bain, B. J. The haematological features of HIV infection. British Journal of Haematology 99, 1-8, doi:10.1046/j.1365-2141.1997.2943111.x (1997).
34 Castella, A., Croxson, T. S., Mildvan, D., Witt, D. H. & Zalusky, R. The bone marrow in AIDS. A histologic, hematologic, and microbiologic study. American journal of clinical pathology 84, 425-432 (1985).
35 Stanley, S. K. et al. CD34+ BONE-MARROW CELLS ARE INFECTED WITH HIV IN A SUBSET OF SEROPOSITIVE INDIVIDUALS. Journal of Immunology 149, 689-697 (1992).
36 Kaczmarski, R. S. et al. DETECTION OF HIV IN HEMATOPOIETIC PROGENITORS. British Journal of Haematology 82, 764-769, doi:10.1111/j.1365-2141.1992.tb06956.x (1992).
37 Moses, A. V. et al. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood 87, 919-925 (1996).
38 Frontiera, M. & Myers, A. M. PERIPHERAL-BLOOD AND BONE-MARROW ABNORMALITIES IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME. Western Journal of Medicine 147, 157-160 (1987).
39 Mir, N., Costello, C., Luckit, J. & Lindley, R. HIV-DISEASE AND BONE-MARROW CHANGES - A STUDY OF 60 CASES. European Journal of Haematology 42, 339-343 (1989).
40 Spivak, J. L., Bender, B. S. & Quinn, T. C. HEMATOLOGIC ABNORMALITIES IN THE ACQUIRED IMMUNE-DEFICIENCY SYNDROME. American Journal of Medicine 77, 224-228, doi:10.1016/0002-9343(84)90695-8 (1984).
41 Camaschella, C. How I manage patients with atypical microcytic anaemia. British Journal of Haematology 160, 12-24, doi:10.1111/bjh.12081 (2013).
42 Straat, M., van Bruggen, R., de Korte, D. & Juffermans, N. P. Red Blood Cell Clearance in Inflammation. Transfusion Medicine and Hemotherapy 39, 353-360, doi:10.1159/000342229 (2012).
43 Patel, K. V., Ferrucci, L., Ershler, W. B., Longo, D. L. & Guralnik, J. M. Red Blood Cell Distribution Width and the Risk of Death in Middle-aged and Older Adults. Archives of Internal Medicine 169, 515-523, doi:10.1001/archinternmed.2009.11 (2009).
44 Douglas, S. W. & Adamson, J. W. ANEMIA OF CHRONIC DISORDERS - STUDIES OF MARROW REGULATION AND IRON-METABOLISM. Blood 45, 55-65 (1975).
45 Weiss, G. & Goodnough, L. T. Medical progress: Anemia of chronic disease. New England Journal of Medicine 352, 1011-1023, doi:10.1056/NEJMra041809 (2005).
46 Miller, A., Green, M. & Robinson, D. SIMPLE RULE FOR CALCULATING NORMAL ERYTHROCYTE SEDIMENTATION-RATE. British Medical Journal 286, 266-266, doi:10.1136/bmj.286.6361.266 (1983).
47 Skalak, R., Zarda, P. R., Jan, K. M. & Chien, S. MECHANICS OF ROULEAU FORMATION. Biophysical Journal 35, 771-781, doi:10.1016/s0006-3495(81)84826-6 (1981).
48 Brigden, M. L. Clinical utility of the erythrocyte sedimentation rate. American Family Physician 60, 1443-1450 (1999).
49 Andresdottir, M. B., Sigfusson, N., Sigvaldason, H. & Gudnason, V. Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women - The Reykjavik study. American Journal of Epidemiology 158, 844-851, doi:10.1093/aje/kwg222 (2003).
50 Pretorius, E. & Kell, D. B. Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases. Integrative Biology 6, 486-510, doi:10.1039/c4ib00025k (2014).
51 Cho, Y.-I. & Cho, D. J. Hemorheology and Microvascular Disorders. Korean Circulation Journal 41, 287-295, doi:10.4070/kcj.2011.41.6.287 (2011).
52 Kesmarky, G., Kenyeres, P., Rabai, M. & Toth, K. Plasma viscosity: A forgotten variable. Clinical Hemorheology and Microcirculation 39, 243-246, doi:10.3233/ch-2008-1088 (2008).
53 Rampling, M. W., Meiselman, H. J., Neu, B. & Baskurt, O. K. Influence of cell-specific factors on red blood cell aggregation. Biorheology 41, 91-112 (2004).
54 Walton, B. L., Byrnes, J. R. & Wolberg, A. S. Fibrinogen, red blood cells, and factor XIII in venous thrombosis. Journal of Thrombosis and Haemostasis 13, S208-S215, doi:10.1111/jth.12918 (2015).
55 Lominadze, D. & Dean, W. L. Involvement of fibrinogen specific binding in erythrocyte aggregation. Febs Letters 517, 41-44, doi:10.1016/s0014-5793(02)02575-9 (2002).
56 Carvalho, F. A. et al. Atomic Force Microscopy-Based Molecular Recognition of a Fibrinogen Receptor on Human Erythrocytes. Acs Nano 4, 4609-4620, doi:10.1021/nn1009648 (2010).
57 De Oliveira, S., Vitorino de Almeida, V., Calado, A., Rosario, H. S. & Saldanha, C. Integrin-associated protein (CD47) is a putative mediator for soluble fibrinogen interaction with human red blood cells membrane. Biochimica Et Biophysica Acta-Biomembranes 1818, 481-490, doi:10.1016/j.bbamem.2011.10.028 (2012).
58 Osime, E. O., Oresanja, O. O. & Okwara, B. U. Packed cell volume Platelet count, PT, PTTK and Fibrinogen concentration of HIV positive patients on antiretroviral drugs. Pakistan Journal of Medical Sciences 31, 1533-1536 (2015).
59 Fox, E. A. & Kahn, S. R. The relationship between inflammation and venous thrombosis - A systematic review of clinical studies. Thrombosis and Haemostasis 94, 362-365, doi:10.1160/th05-04-0266 (2005).
60 Chirinos, J. A. et al. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. Journal of the American College of Cardiology 45, 1467-1471, doi:10.1016/j.jacc.2004.12.075 (2005).
61 Gabay, C. Mechanisms of disease - Acute-phase proteins and other systemic responses to inflammation (vol 340, pg 448, 1999). New England Journal of Medicine 340, 1376-1376 (1999).
62 Zon, L. I. & Groopman, J. E. HEMATOLOGIC MANIFESTATIONS OF THE HUMAN IMMUNE-DEFICIENCY VIRUS (HIV). Seminars in Hematology 25, 208-218 (1988).
63 Boelaert, J. R., Weinberg, G. A. & Weinberg, E. D. Altered iron metabolism in HIV infection: Mechanisms, possible consequences, and proposals for management. Infectious Agents and Disease-Reviews Issues and Commentary 5, 36-46 (1996).
64 Waldvogel-Abramowski, S. et al. Physiology of Iron Metabolism. Transfusion Medicine and Hemotherapy 41, 213-221, doi:10.1159/000362888 (2014).
65 Lau, B. et al. C-reactive protein is a marker for human immunodeficiency virus disease progression. Archives of Internal Medicine 166, 64-70, doi:10.1001/archinte.166.1.64 (2006).
66 Dolan, S. E. et al. Increased cardiovascular disease risk indices in HIV-infected women. Jaids-Journal of Acquired Immune Deficiency Syndromes 39, 44-54, doi:10.1097/01.qai.0000159323.59250.83 (2005).
67 Arinola, O. G., Adedapo, K. S., Kehinde, A. O., Olaniyi, J. A. & Akiibinu, M. O. Acute phase proteins, trace elements in asymptomatic human immunodeficiency virus infection in Nigerians. African journal of medicine and medical sciences 33, 317-322 (2004).
68 Noursadeghi, M. & Miller, R. F. Clinical value of C-reactive protein measurements in HIV-positive patients. International Journal of Std & Aids 16, 438-441 (2005).
69 Madden, E. et al. Association of antiretroviral therapy with fibrinogen levels in HIV-infection. Aids 22, 707-715, doi:10.1097/QAD.0b013e3282f560d9 (2008).
70 Reingold, J. S. et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels - The Fat Redistribution and Metabolic Change in HIV Infection (FRAM) study. Jaids-Journal of Acquired Immune Deficiency Syndromes 48, 142-148, doi:10.1097/QAI.0b013e3181685727 (2008).
71 Tien, P. C. et al. Inflammation and Mortality in HIV-Infected Adults: Analysis of the FRAM Study Cohort. Jaids-Journal of Acquired Immune Deficiency Syndromes 55, 316-322, doi:10.1097/QAI.0b013e3181e66216 (2010).
72 Chaudhary, M., Kashyap, B., Gautam, H., Saini, S. & Bhalla, P. Role of C-reactive protein in HIV infection: A pilot study. Viral Immunology 21, 263-266, doi:10.1089/vim.2007.0083 (2008).
73 Fitzsimons, E. J. & Brock, J. H. The anaemia of chronic disease - Remains hard to distinguish from iron deficiency anaemia in some cases. British Medical Journal 322, 811-812, doi:10.1136/bmj.322.7290.811 (2001).
74 Kell, D. B. & Pretorius, E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics 6, 748-773, doi:10.1039/c3mt00347g (2014).
75 Hung, S.-H., Lin, H.-C. & Chung, S.-D. Association between venous thromboembolism and iron-deficiency anemia: a population-based study. Blood Coagulation & Fibrinolysis 26, 368-372, doi:10.1097/mbc.0000000000000249 (2015).
76 Urrechaga, E., Hoffmann, J. J. M. L., Izquierdo, S. & Escanero, J. F. Differential diagnosis of microcytic anemia: the role of microcytic and hypochromic erythrocytes. International Journal of Laboratory Hematology 37, 334-340, doi:10.1111/ijlh.12290 (2015).
77 Stoltzfus, R. J. Defining iron-deficiency anemia in public health terms: A time for reflection. Journal of Nutrition 131, 565S-567S (2001).
78 Fuchs, D. et al. IMMUNE ACTIVATION AND THE ANEMIA ASSOCIATED WITH CHRONIC INFLAMMATORY DISORDERS. European Journal of Haematology 46, 65-70 (1991).
79 Perkocha, L. A. & Rodgers, G. M. HEMATOLOGIC ASPECTS OF HUMAN IMMUNODEFICIENCY VIRUS-INFECTION - LABORATORY AND CLINICAL CONSIDERATIONS. American Journal of Hematology 29, 94-105, doi:10.1002/ajh.2830290207 (1988).
80 Minchella, P. A. et al. Elevated Hepcidin Is Part of a Complex Relation That Links Mortality with Iron Homeostasis and Anemia in Men and Women with HIV Infection. Journal of Nutrition 145, 1194-1201, doi:10.3945/jn.114.203158 (2015).
81 Nemeth, E. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090-2093, doi:10.1126/science.1104742 (2004).
82 Jonker, F. A. M. & van Hensbroek, M. B. Anaemia, iron deficiency and susceptibility to infections. Journal of Infection 69, S23-S27, doi:10.1016/j.jinf.2014.08.007 (2014).
83 Pretorius, E. et al. Ultrastructural changes in platelet aggregates of HIV patients: A scanning electron microscopy study. Ultrastructural Pathology 32, 75-79, doi:10.1080/01913120802034793 (2008).
84 Pretorius, E. et al. Investigating the ultrastructure of platelets of HIV patients treated with the immuno-regulator, Canova: a qualitative scanning electron microscopy study. Histology and Histopathology 24, 399-405 (2009).
85 Jackson, B. S. & Mokoena, T. Comparison of the therapeutic dose of warfarin in HIV-infected and HIV-uninfected patients: a study of clinical practice. Bmj Open 7, doi:10.1136/bmjopen-2016-013709 (2017).
86 Majluf-Cruz, A. et al. Venous thrombosis among patients with AIDS. Clinical and Applied Thrombosis-Hemostasis 10, 19-25, doi:10.1177/107602960401000104 (2004).
87 Haugaard, A. K. et al. Discrepant coagulation profile in HIV infection: elevated D-dimer but impaired platelet aggregation and clot initiation. Aids 27, 2749-2758, doi:10.1097/01.aids.0000432462.21723.ed (2013).
88 Ronsholt, F. F. et al. Thromboelastography on plasma reveals delayed clot formation and accelerated clot lyses in HIV-1 infected persons compared with healthy controls. Bmc Infectious Diseases 15, doi:10.1186/s12879-015-1124-4 (2015).
89 Nordell, A. D. et al. Severity of Cardiovascular Disease Outcomes Among Patients With HIV Is Related to Markers of Inflammation and Coagulation. Journal of the American Heart Association 3, doi:10.1161/jaha.114.000844 (2014).
90 Pretorius, E., Olumuyiwa-Akeredolu, O.-o. O., Mbotwe, S. & Bester, J. Erythrocytes and their role as health indicator: Using structure in a patient-orientated precision medicine approach. Blood Reviews 30, 263-274, doi:10.1016/j.blre.2016.01.001 (2016).
91 Swanepoel, A. C. & Pretorius, E. Scanning electron microscopy analysis of erythrocytes in thromboembolic ischemic stroke. International Journal of Laboratory Hematology 34, 185-191, doi:10.1111/j.1751-553X.2011.01379.x (2012).
92 Santos-Silva, A. et al. Erythrocyte damage and leukocyte activation in ischemic stroke. Clinica Chimica Acta 320, 29-35 (2002).
93 Robinson, J. M. Reactive oxygen species in phagocytic leukocytes. Histochemistry and Cell Biology 130, 281-297, doi:10.1007/s00418-008-0461-4 (2008).
94 Pretorius, E. et al. Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics. Cardiovascular Diabetology 14, doi:10.1186/s12933-015-0192-5 (2015).
95 Pretorius, E., du Plooy, J., Soma, P. & Gasparyan, A. Y. An ultrastructural analysis of platelets, erythrocytes, white blood cells, and fibrin network in systemic lupus erythematosus. Rheumatology International 34, 1005-1009, doi:10.1007/s00296-013-2817-x (2014).
96 Pretorius, E. et al. Eryptosis as a marker of Parkinson's disease. Aging-Us 6, 788-819, doi:10.18632/aging.100695 (2014).
97 Bester, J., Soma, P., Kell, D. B. & Pretorius, E. Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS). Oncotarget 6, 35284-35303, doi:10.18632/oncotarget.6074 (2015).
98 Lang, K. S. et al. Involvement of ceramide in hyperosmotic shock-induced death of erythrocytes. Cell Death and Differentiation 11, 231-243, doi:10.1038/sj.cdd.4401311 (2004).
99 Sirachainan, N. et al. Normalized coagulation markers and anticoagulation proteins in children with severe beta-thalassemia disease after stem cell transplantation. Thrombosis Research 129, 765-770, doi:10.1016/j.thromres.2011.07.046 (2012).
100 Kempe, D. S. et al. Suicidal erythrocyte death in sepsis. Journal of Molecular Medicine-Jmm 85, 269-277, doi:10.1007/s00109-006-0123-8 (2007).
101 Lang, F., Lang, E. & Foeller, M. Physiology and Pathophysiology of Eryptosis. Transfusion Medicine and Hemotherapy 39, 308-314, doi:10.1159/000342534 (2012).
102 Lang, F. & Qadri, S. M. Mechanisms and Significance of Eryptosis, the Suicidal Death of Erythrocytes. Blood Purification 33, 125-130, doi:10.1159/000334163 (2012).
103 Litvinov, R. I. & Weisel, J. W. Role of red blood cells in haemostasis and thrombosis. ISBT science series 12, 176-183, doi:10.1111/voxs.12331 (2017).
104 Schroit, A. J. & Zwaal, R. F. A. TRANSBILAYER MOVEMENT OF PHOSPHOLIPIDS IN RED-CELL AND PLATELET MEMBRANES. Biochimica Et Biophysica Acta 1071, 313-329, doi:10.1016/0304-4157(91)90019-s (1991).
105 Pajic-Lijakovic, I. Erythrocytes under osmotic stress - modeling considerations. Progress in Biophysics & Molecular Biology 117, 113-124, doi:10.1016/j.pbiomolbio.2014.11.003 (2015).
106 Thevenin, B. J. M. & Low, P. S. KINETICS AND REGULATION OF THE ANKYRIN-BAND-3 INTERACTION OF THE HUMAN RED-BLOOD-CELL MEMBRANE. Journal of Biological Chemistry 265, 16166-16172 (1990).
107 Davis, L. H., Otto, E. & Bennett, V. SPECIFIC 33-RESIDUE REPEAT(S) OF ERYTHROCYTE ANKYRIN ASSOCIATE WITH THE ANION-EXCHANGER. Journal of Biological Chemistry 266, 11163-11169 (1991).
108 Burton, N. M. & Bruce, L. J. Modelling the structure of the red cell membrane. Biochemistry and Cell Biology 89, 200-215, doi:10.1139/o10-154 (2011).
109 Grey, J. L., Kodippili, G. C., Simon, K. & Low, P. S. Identification of Contact Sites between Ankyrin and Band 3 in the Human Erythrocyte Membrane. Biochemistry 51, 6838-6846, doi:10.1021/bi300693k (2012).
110 Czogalla, A. & Sikorski, A. F. Do we already know how spectrin attracts ankyrin? Cellular and Molecular Life Sciences 67, 2679-2683, doi:10.1007/s00018-010-0371-1 (2010).
111 Cunha, S. R. & Mohler, P. J. Ankyrin protein networks in membrane formation and stabilization. Journal of Cellular and Molecular Medicine 13, 4364-4376, doi:10.1111/j.1582-4934.2009.00943.x (2009).
112 Devaux, P. F., Herrmann, A., Ohlwein, N. & Koziov, M. M. How lipid flippases can modulate membrane structure. Biochimica Et Biophysica Acta-Biomembranes 1778, 1591-1600, doi:10.1016/j.bbamem.2008.03.007 (2008).
113 Clark, M. R. Flippin' lipids. Nature Immunology 12, 373-375, doi:10.1038/ni.2024 (2011).
114 Powell, R. J., Machiedo, G. W., Rush, B. F. & Dikdan, G. OXYGEN FREE-RADICALS - EFFECT ON RED-CELL DEFORMABILITY IN SEPSIS. Critical Care Medicine 19, 732-735, doi:10.1097/00003246-199105000-00022 (1991).
115 Mallat, Z. et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 101, 841-843 (2000).
116 Koch, C. G. et al. Duration of red-cell storage and complications after cardiac surgery. New England Journal of Medicine 358, 1229-1239, doi:10.1056/NEJMoa070403 (2008).
117 van Beers, E. J. et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica-the Hematology Journal 94, 1513-1519, doi:10.3324/haematol.2009.008938 (2009).
118 Zecher, D., Cumpelik, A. & Schifferli, J. A. Erythrocyte-Derived Microvesicles Amplify Systemic Inflammation by Thrombin-Dependent Activation of Complement. Arteriosclerosis Thrombosis and Vascular Biology 34, 313-320, doi:10.1161/atvbaha.113.302378 (2014).
119 Eyal, A. & Veller, M. HIV and venous thrombotic events. South African Journal of Surgery 47, 54-56 (2009).
120 Wohner, N. et al. Lytic Resistance of Fibrin Containing Red Blood Cells. Arteriosclerosis Thrombosis and Vascular Biology 31, 2306-U2343, doi:10.1161/atvbaha.111.229088 (2011).
121 Varin, R. et al. Whole blood clots are more resistant to lysis than plasma clots - greater efficacy of rivaroxaban. Thrombosis Research 131, E100-E109, doi:10.1016/j.thromres.2012.11.029 (2013).
122 Pretorius, E. & Lipinski, B. Thromboembolic ischemic stroke changes red blood cell morphology. Cardiovascular Pathology 22, 241-242, doi:10.1016/j.carpath.2012.11.005 (2013).
123 Cines, D. B. et al. Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin. Blood 123, 1596-1603, doi:10.1182/blood-2013-08-523860 (2014).
124 Reikvam, H. et al. Thrombelastography. Transfusion and Apheresis Science 40, 119-123, doi:10.1016/j.transci.2009.01.019 (2009).
125 Braekkan, S. K. et al. Mean platelet volume is a risk factor for venous thromboembolism: the Troms circle divide study. Journal of Thrombosis and Haemostasis 8, 157-162, doi:10.1111/j.1538-7836.2009.03498.x (2010).
126 Coban, E., Yazicioglu, G., Avci, A. B. & Akcit, F. The mean platelet volume in patients with essential and white coat hypertension. Platelets 16, 435-438, doi:10.1080/09537100500163572 (2005).
127 Nadar, S. K., Blann, A. D., Kamath, S., Beevers, D. G. & Lip, G. Y. H. Platelet indexes in relation to target organ damage in high-risk hypertensive patients - A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Journal of the American College of Cardiology 44, 415-422, doi:10.1016/j.jacc.2004.03.067 (2004).
128 Papanas, N. et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 15, 475-478, doi:10.1080/0953710042000267707 (2004).
129 Nadar, S. K., Lip, G. Y. & Blann, A. D. Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke - The West Birmingham Stroke Project. Thrombosis and Haemostasis 92, 1342-1348, doi:10.1160/th04-07-0433 (2004).
130 Greisenegger, S. et al. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke 35, 1688-1691, doi:10.1161/01.STR.0000130512.81212.a2 (2004).
131 Martin, J. F., Bath, P. M. W. & Burr, M. L. INFLUENCE OF PLATELET SIZE ON OUTCOME AFTER MYOCARDIAL-INFARCTION. Lancet 338, 1409-1411, doi:10.1016/0140-6736(91)92719-i (1991).
132 Vagdatli, E. et al. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia 14, 28-32 (2010).
133 Gasparyan, A. Y., Ayvazyan, L., Mikhailidis, D. P. & Kitas, G. D. Mean Platelet Volume: A Link Between Thrombosis and Inflammation? Current Pharmaceutical Design 17, 47-58 (2011).
134 Prandoni, P. Venous and arterial thrombosis: Two aspects of the same disease? European Journal of Internal Medicine 20, 660-661, doi:10.1016/j.ejim.2009.02.001 (2009).
135 Swanepoel, A. C., Nielsen, V. G. & Pretorius, E. Viscoelasticity and Ultrastructure in Coagulation and Inflammation: Two Diverse Techniques, One Conclusion. Inflammation 38, 1707-1726, doi:10.1007/s10753-015-0148-7 (2015).
136 Gresele, P., Falcinelli, E., Sebastiano, M. & Baldelli, F. Endothelial and platelet function alterations in HIV-infected patients. Thrombosis Research 129, 301-308, doi:10.1016/j.thromres.2011.11.022 (2012).
137 Youssefian, T., Drouin, A., Masse, J. M., Guichard, J. & Cramer, E. M. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood 99, 4021-4029, doi:10.1182/blood-2001-12-0191 (2002).
138 Metcalf Pate, K. A. & Mankowski, J. L. HIV and SIV Associated Thrombocytopenia: An Expanding Role for Platelets in the Pathogenesis of HIV. Drug discovery today. Disease mechanisms 8, e25-e32 (2011).
139 Sandler, D. A. & Martin, J. F. Autopsy Proven Pulmonary Embolism in Hospital Patients: Are We Detecting Enough Deep Vein Thrombosis? Journal of the Royal Society of Medicine 82, 203-205, doi:10.1177/014107688908200407 (1989).
140 Meignan, M. et al. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med 160, 159-164 (2000).
141 Jackson, B. S. & Pretorius, E. Pathological Clotting and Deep Vein Thrombosis in Patients with HIV. Seminars in thrombosis and hemostasis, doi:10.1055/s-0038-1676374 (2018).